doi: 10.1038/s41571-025-01023-z.
Durable responses to belzutifan in patients with VHL disease
Affiliations
- PMID: 40281323
- DOI: 10.1038/s41571-025-01023-z
Item in Clipboard
Durable responses to belzutifan in patients with VHL disease
Nat Rev Clin Oncol.
2025 Jun.
No abstract available
Similar articles
-
Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.Future Oncol. 2024;20(18):1251-1266. doi: 10.2217/fon-2023-0679. Epub 2024 Apr 19. Future Oncol. 2024. PMID: 38639572 Free PMC article. Review.
-
Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature.Ocul Oncol Pathol. 2024 Sep;10(3):154-161. doi: 10.1159/000539434. Epub 2024 May 24. Ocul Oncol Pathol. 2024. PMID: 39224523 Free PMC article.
-
First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.CNS Oncol. 2022 Jul 12;11(3):CNS91. doi: 10.2217/cns-2022-0008. Online ahead of print. CNS Oncol. 2022. PMID: 35819008 Free PMC article.
-
Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.J Natl Compr Canc Netw. 2022 Dec;20(12):1285-1287. doi: 10.6004/jnccn.2022.7047. J Natl Compr Canc Netw. 2022. PMID: 36509068
-
Belzutifan for the treatment of renal cell carcinoma.Ther Adv Med Oncol. 2025 Feb 8;17:17588359251317846. doi: 10.1177/17588359251317846. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39926260 Free PMC article. Review.
References
Original article
-
- Srinivasan, R. et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(25)00099-3 (2025) - DOI - PubMed
LinkOut - more resources
Full Text Sources
